Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New biotechnology holding company ElevateBio launches in Cambridge, US
ElevateBio is backed by $150m funding raised through a Series A financing round co-led by the MPM Capital-managed UBS Oncology Impact Fund and F2 Ventures. Other investors in
ElevateBio is backed by $150m funding raised through a Series A financing round co-led by the MPM Capital-managed UBS Oncology Impact Fund and F2 Ventures. Other investors in
With Daiichi Sankyo’s first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under the terms of the companies’ collaboration agreement.
The results demonstrated Gilenya 0.5mg’s superior efficacy over glatiramer acetate 20mg in reducing the annualized relapse rate (ARR), a key measure of disease activity, with a 40.7% relative
SEP-363856 was discovered by Sunovion in collaboration with PsychoGenics using the in vivo phenotypic SmartCube platform and the artificial intelligence algorithms associated with it. Its breakthrough therapy designation
Through the early-stage trial called DUET-3, Xencor will assess the safety and tolerability of XmAb23104 in an estimated 144 patients with selected advanced solid tumors. The participants will
The latest approval for Kadcyla is for HER2-positive early breast cancer patients with residual invasive disease after being subjected to neoadjuvant treatment with taxane and Herceptin (trastuzumab). The
Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20
Headquartered in California, Abide has developed a platform to discover potent and selective serine hydrolase inhibitors. The platform is used by the company to identify, develop, and validate
Pear Therapeutics is developing Pear-006 in collaboration with Novartis under the terms of an agreement announced in March 2018. Clinicians estimate that between 35-50% of people with MS
Innovative oncolytic viruses resulting from this collaboration will use Transgene’s proprietary next generation viral platform Invir.IO. Under the terms of the agreement Transgene will contribute its oncolytic virus